Developer docs
API playgroundTry for free, no card

Search company profiles

POP Biotechnologies

Full company profile

uuid0054jm9

Namestring
POP Biotechnologies
Legal namestring
POP Biotechnologies, Inc.
Websiteurl
pop.bio
Company typeenum
Private
Founded yearint
2016
Descriptiontext

POP Biotechnologies (POP BIO) is a privately held biotechnology company founded in 2016 in Buffalo, New York, that develops proprietary nanomedicine platforms based on porphyrin-phospholipid (PoP) liposome technology exclusively licensed from the State University of New York Research Foundation. Its flagship SNAP (Spontaneous Nanoliposome Antigen Particleization) platform uses cobalt-modified PoP liposomes (CoPoP) to enable stable, rapid display of protein and peptide antigens on nanoparticles, producing vaccine candidates in minutes rather than months while achieving antigen sparing to under $0.04 per human dose. The clinical pipeline includes EuCorVac-19 (COVID-19, Phase 3 primary endpoint met with EuBiologics), EuRSV (RSV, Phase 1) and EuHZV (shingles, Phase 1), with preclinical candidates in seasonal influenza (SNAP-Flu), Alzheimer's disease (PADIVAX), melanoma immunotherapy, and light-activated chemophototherapy (PhotoDOX for solid tumors).

POP BIO operates a partnership-led go-to-market model rather than direct commercialization. Revenue is generated through technology licensing, milestone payments, and royalties via the EuPOP Life Sciences joint venture with South Korea-based EuBiologics, which handles antigen production, manufacturing scale-up at 1000L bioreactors, and global commercialization of vaccine candidates. The company supplements partner-funded programs with substantial non-dilutive funding from US federal agencies (NIH, NCI, NIAID, NIA) and CEPI, totaling roughly $18.5M across multiple Phase II STTR and SBIR grants plus a $9.7M CEPI award for H5N1 avian influenza and Disease X preparedness. Customers and end users are pharmaceutical companies, government agencies (CEPI, NIH), and ultimately public health systems and patients receiving vaccines for infectious disease, oncology, and neurodegenerative indications.

The company serves infectious disease prevention (COVID-19, RSV, shingles, influenza, H5N1, SFTS, Disease X), oncology and immuno-oncology (melanoma, hepatocellular carcinoma, breast cancer via PhotoDOX chemophototherapy and cancer vaccines), and neurodegenerative disease (Alzheimer's mosaic immunotherapy). Revenue mechanics rely on a single dominant licensee (EuBiologics) and grant funding; no venture equity rounds are disclosed in source materials, and products have not yet generated commercial sales.

Short descriptiontext

POP Biotechnologies is a privately held Buffalo, NY biotech that develops the SNAP nanoliposome vaccine platform, licensing it to pharmaceutical partners (primarily EuBiologics) for clinical development and commercialization across infectious disease, oncology, and neurodegenerative indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBuffalo, United States
HQ citystring
Buffalo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanoparticle vaccine development, liposome drug delivery, biopharmaceutical platform technology, infectious disease vaccines, cancer immunotherapy
Industry2 codes
PRIMARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

POP BIO licenses its proprietary PoP and SNAP technology platforms to pharmaceutical and biotechnology partners. Revenue is generated through licensing fees, development milestones, and royalties on commercialized products.

pop.bio
2Government Grants and Funding
TypeProfessional Services
Description

The company receives significant non-dilutive funding from government agencies including NIH, CEPI, and other federal funding programs to support platform development and clinical programs.

pop.bio
3Co-development and Joint Ventures
TypeLicensing Royalties
Description

Strategic partnerships and joint ventures such as EuPOP Life Sciences for co-development and commercialization of pipeline products.

pop.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1SNAP™ (Spontaneous Nanoliposome Antigen Particleization)
Description

Core platform technology enabling rapid development of highly immunogenic particle-based vaccines and immunotherapies using cobalt-modified porphyrin-phospholipid liposomes (CoPoP).

pop.bio
+6 more records
Core offering1 text field

POP Biotechnologies develops proprietary porphyrin-phospholipid (PoP) liposome-based nanomedicine platforms, centered on the SNAP (Spontaneous Nanoliposome Antigen Particleization) vaccine platform that uses cobalt-modified CoPoP liposomes to rapidly display antigens. The company licenses this platform to pharmaceutical partners (notably EuBiologics) for co-development and commercialization of vaccines (COVID-19, RSV, shingles, influenza, H5N1, Alzheimer's) and develops the PhotoDOX light-activated chemotherapy product for solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • SNAP generates vaccine candidates in minutes vs. months for typical competitors
+7 more records
Product overview1 text field

POP Biotechnologies develops proprietary nanomedicine platforms centered on its porphyrin-phospholipid (PoP) liposome technology and the SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform. The SNAP platform enables rapid development of highly immunogenic particle-based vaccines by using cobalt-modified CoPoP liposomes that stably bind and display protein and peptide antigens. The product portfolio includes vaccine products in clinical development: EuCorVac-19 (COVID-19, Phase 3 completed with EuBiologics), EuRSV (RSV, Phase 1), and EuHZV (shingles, Phase 1), along with pipeline candidates including SNAP-Flu (influenza), PADIVAX™ (Alzheimer's disease), and SNAP H5N1 (avian influenza). The PhotoDOX™ chemo-phototherapy product addresses solid tumor cancer treatment using light-activated drug delivery. The company operates through its EuPOP Life Sciences joint venture with EuBiologics for global vaccine commercialization.

Product and service2 records
1SNAP (Spontaneous Nanoliposome Antigen Particleization) Platform
CategoryBiopharmaceutical Platform Technology
Description

Proprietary platform technology enabling rapid development of highly immunogenic particle-based vaccines and immunotherapies through cobalt-modified porphyrin-phospholipid liposomes (CoPoP) that stably and spontaneously display protein and peptide antigens via His-tag membrane anchoring. Licensed to pharmaceutical and biotechnology partners for vaccine and immunotherapy development.

2PoP (Porphyrin-Phospholipid) Liposome Technology
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-08-21
Description

Japanese partner for antibody-inducing peptide therapy collaboration. FunPep's peptides combined with SNAP platform for enhanced therapeutic antibody production. Advancing to advanced preclinical testing for undisclosed chronic disease indication.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

NIH-funded collaboration for hepatocellular carcinoma treatment using PhotoDox (I-CPT). Gal Shafirstein's group at Roswell Park collaborates on interstitial chemo-phototherapy development. Part of $2M NIH-NCI Phase II STTR.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

South Korean pharmaceutical partner co-developing multiple vaccines using POP BIO's SNAP technology. Partnership on EuCorVac-19 (COVID-19, Phase 3 completed), RSV vaccine (Phase 1), shingles vaccine (Phase 1). EuBiologics provides antigen production, EcML adjuvant, and manufacturing scale-up with capacity for hundreds of millions of doses.

4EuPOP Life Sciences
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Joint venture between POP BIO and EuBiologics based in Buffalo, NY for global commercialization of vaccines using POP BIO's SNAP platform and EuBiologics' EcML adjuvant technology. Advancing RSV, shingles, and Alzheimer's disease vaccines toward clinical trials.

pop.bio
Strategic tierCoreTypeStrategic or Co-development Partner
Description

POP BIO operates from SUNY Buffalo incubator at Baird Research Park. Co-founder Dr. Jonathan Lovell developed the PoP technology at University at Buffalo. Ongoing research collaborations for vaccine development.

6SUNY Upstate Medical University
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

International research team collaboration for SNAP platform development against Disease X threats.

pop.bio
7National Institute of Infectious Diseases (Japan)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

International research team collaboration as part of CEPI-funded SNAP platform project for SFTS and Disease X preparedness.

pop.bio
8New York State Institute for Basic Research in Developmental Disabilities
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration on Alzheimer's immunotherapy with Dr. Chunling Dai as co-investigator. Part of $2.46M NIH Phase II STTR grant for mosaic SNAP active immunotherapy development.

pop.bio
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration on Alzheimer's immunotherapy research as part of NIH-funded mosaic SNAP vaccine program.

10Janssen Vaccines (Johnson & Johnson)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration resulted in HIV-1 vaccine candidate research published in Nature Communications. SNAP platform used with HIV-1 Env trimers to generate cross-clade neutralizing antibody immunity.

pop.bio
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

POP BIO's cancer vaccine concept accepted into NCL's Assay Cascade characterization program for rigorous evaluation including sterility, endotoxin testing, physicochemical characterization, and in vivo studies to promote clinical translation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GSK's vaccines business is a global leader with established franchises in shingles (Shingrix), HPV, and influenza. Directly relevant as the dominant commercial competitor in the shingles vaccine category where POP BIO's EuHZV is in Phase 1.

TypeDirect peer
Description

Soligenix is a late-stage clinical biopharmaceutical company developing vaccines and therapeutics for infectious disease and rare conditions. Comparable as a small, clinical-stage vaccine biotech pursuing partnered development of platform-derived products.

TypeEmerging player
Description

CureVac is an mRNA technology company developing prophylactic vaccines and cancer immunotherapies. Comparable as a platform-based vaccine developer pursuing infectious disease and oncology applications, though with a different underlying technology than POP BIO's liposome-based SNAP platform.

4Sanofi Pasteur
TypeBroad incumbent
Description

Sanofi Pasteur is one of the world's largest vaccine manufacturers with a portfolio spanning influenza, pediatric, and travel vaccines. Represents the established incumbent in the vaccine market that POP BIO's partnered programs ultimately compete against for share.

TypeDirect peer
Description

Dynavax specializes in vaccine adjuvants (CpG 1018) and commercializes hepatitis B and COVID-19 vaccines. Comparable as a vaccine platform company whose adjuvant technology (similar to EuBiologics' EcML used with SNAP) is central to its partnership-based business model.

TypeDirect peer
Description

VBI Vaccines is a clinical-stage vaccine platform company developing enveloped virus-like particle (eVLP) vaccines for infectious disease and immuno-oncology. Comparable as a small-cap, platform-licensed vaccine developer pursuing partnership-driven commercialization.

TypeBroad incumbent
Description

BioNTech pioneered mRNA vaccine technology and partnered with Pfizer for the Comirnaty COVID-19 vaccine. Its platform addresses infectious disease and oncology, directly overlapping with POP BIO's target therapeutic areas and partnership-driven GTM model.

TypeBroad incumbent
Description

Moderna is the leading mRNA vaccine platform company, with an established commercial COVID-19 vaccine franchise and pipeline spanning infectious disease, oncology, and rare disease. It represents the dominant competitive force in rapid-response vaccine development that POP BIO's SNAP platform must differentiate against.

TypeDirect peer
Description

Gritstone bio develops neoantigen-based cancer vaccines and infectious disease vaccines using a self-amplifying mRNA platform combined with adenoviral vectors. Comparable as a clinical-stage biotech applying vaccine platform technology to oncology and infectious disease indications.

TypeDirect peer
Description

Novavax develops protein nanoparticle vaccines using recombinant nanoparticle technology with a built-in Matrix-M adjuvant, making it the closest structural analog to POP BIO's SNAP/CoPoP liposome platform. Both companies target infectious disease vaccine indications and pursue licensing/partnership models with global manufacturers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

POP Biotechnologies

Biopharmaceuticalspop.bio

POP Biotechnologies is a privately held Buffalo, NY biotech that develops the SNAP nanoliposome vaccine platform, licensing it to pharmaceutical partners (primarily EuBiologics) for clinical development and commercialization across infectious disease, oncology, and neurodegenerative indications.

What POP Biotechnologies does

POP Biotechnologies (POP BIO) is a privately held biotechnology company founded in 2016 in Buffalo, New York, that develops proprietary nanomedicine platforms based on porphyrin-phospholipid (PoP) liposome technology exclusively licensed from the State University of New York Research Foundation. Its flagship SNAP (Spontaneous Nanoliposome Antigen Particleization) platform uses cobalt-modified PoP liposomes (CoPoP) to enable stable, rapid display of protein and peptide antigens on nanoparticles, producing vaccine candidates in minutes rather than months while achieving antigen sparing to under $0.04 per human dose. The clinical pipeline includes EuCorVac-19 (COVID-19, Phase 3 primary endpoint met with EuBiologics), EuRSV (RSV, Phase 1) and EuHZV (shingles, Phase 1), with preclinical candidates in seasonal influenza (SNAP-Flu), Alzheimer's disease (PADIVAX), melanoma immunotherapy, and light-activated chemophototherapy (PhotoDOX for solid tumors).

POP BIO operates a partnership-led go-to-market model rather than direct commercialization. Revenue is generated through technology licensing, milestone payments, and royalties via the EuPOP Life Sciences joint venture with South Korea-based EuBiologics, which handles antigen production, manufacturing scale-up at 1000L bioreactors, and global commercialization of vaccine candidates. The company supplements partner-funded programs with substantial non-dilutive funding from US federal agencies (NIH, NCI, NIAID, NIA) and CEPI, totaling roughly $18.5M across multiple Phase II STTR and SBIR grants plus a $9.7M CEPI award for H5N1 avian influenza and Disease X preparedness. Customers and end users are pharmaceutical companies, government agencies (CEPI, NIH), and ultimately public health systems and patients receiving vaccines for infectious disease, oncology, and neurodegenerative indications.

The company serves infectious disease prevention (COVID-19, RSV, shingles, influenza, H5N1, SFTS, Disease X), oncology and immuno-oncology (melanoma, hepatocellular carcinoma, breast cancer via PhotoDOX chemophototherapy and cancer vaccines), and neurodegenerative disease (Alzheimer's mosaic immunotherapy). Revenue mechanics rely on a single dominant licensee (EuBiologics) and grant funding; no venture equity rounds are disclosed in source materials, and products have not yet generated commercial sales.

POP Biotechnologies firmographics

Firmographics
Name
POP Biotechnologies
Legal name
POP Biotechnologies, Inc.
Website
https://pop.bio
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
POP Biotechnologies is a privately held Buffalo, NY biotech that develops the SNAP nanoliposome vaccine platform, licensing it to pharmaceutical partners (primarily EuBiologics) for clinical development and commercialization across infectious disease, oncology, and neurodegenerative indications.
Ownership category
akta.pro rank

POP Biotechnologies industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Nanoparticle vaccine development
  • Liposome drug delivery
  • Biopharmaceutical platform technology
  • Infectious disease vaccines
  • Cancer immunotherapy

Where POP Biotechnologies is headquartered

Location

Headquarters

HQ city
Buffalo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

POP Biotechnologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing: POP BIO licenses its proprietary PoP and SNAP technology platforms to pharmaceutical and biotechnology partners. Revenue is generated through licensing fees, development milestones, and royalties on commercialized products.
  2. Government Grants and Funding: The company receives significant non-dilutive funding from government agencies including NIH, CEPI, and other federal funding programs to support platform development and clinical programs.
  3. Co-development and Joint Ventures: Strategic partnerships and joint ventures such as EuPOP Life Sciences for co-development and commercialization of pipeline products.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

POP Biotechnologies product offering

Product offering

Core offering

POP Biotechnologies develops proprietary porphyrin-phospholipid (PoP) liposome-based nanomedicine platforms, centered on the SNAP (Spontaneous Nanoliposome Antigen Particleization) vaccine platform that uses cobalt-modified CoPoP liposomes to rapidly display antigens. The company licenses this platform to pharmaceutical partners (notably EuBiologics) for co-development and commercialization of vaccines (COVID-19, RSV, shingles, influenza, H5N1, Alzheimer's) and develops the PhotoDOX light-activated chemotherapy product for solid tumors.

Product overview

POP Biotechnologies develops proprietary nanomedicine platforms centered on its porphyrin-phospholipid (PoP) liposome technology and the SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform. The SNAP platform enables rapid development of highly immunogenic particle-based vaccines by using cobalt-modified CoPoP liposomes that stably bind and display protein and peptide antigens. The product portfolio includes vaccine products in clinical development: EuCorVac-19 (COVID-19, Phase 3 completed with EuBiologics), EuRSV (RSV, Phase 1), and EuHZV (shingles, Phase 1), along with pipeline candidates including SNAP-Flu (influenza), PADIVAX™ (Alzheimer's disease), and SNAP H5N1 (avian influenza). The PhotoDOX™ chemo-phototherapy product addresses solid tumor cancer treatment using light-activated drug delivery. The company operates through its EuPOP Life Sciences joint venture with EuBiologics for global vaccine commercialization.

Differentiator

Problem solved

Functional benefit

Brands

  • SNAP™ (Spontaneous Nanoliposome Antigen Particleization): Core platform technology enabling rapid development of highly immunogenic particle-based vaccines and immunotherapies using cobalt-modified porphyrin-phospholipid liposomes (CoPoP).
  • PhotoDOX™
  • EuCorVac-19
  • EuRSV
  • EuHZV
  • PADIVAX™
  • SNAPflu

Products and services

  • SNAP (Spontaneous Nanoliposome Antigen Particleization) Platform Proprietary platform technology enabling rapid development of highly immunogenic particle-based vaccines and immunotherapies through cobalt-modified porphyrin-phospholipid liposomes (CoPoP) that stably and spontaneously display protein and peptide antigens via His-tag membrane anchoring. Licensed to pharmaceutical and biotechnology partners for vaccine and immunotherapy development.
  • PoP (Porphyrin-Phospholipid) Liposome Technology

Quantifiable outcome

  • SNAP generates vaccine candidates in minutes vs. months for typical competitors
  • +7 more outcomes

Companies that use POP Biotechnologies

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

POP Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

POP Biotechnologies partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered supporting, flagship and core.

  • FunPep Co., Ltd.supportingStrategic or Co-development Partner · 21 August 2024Japanese partner for antibody-inducing peptide therapy collaboration. FunPep's peptides combined with SNAP platform for enhanced therapeutic antibody production. Advancing to advanced preclinical testing for undisclosed chronic disease indication.
  • Roswell Park Comprehensive Cancer CentersupportingStrategic or Co-development Partner · 1 February 2023NIH-funded collaboration for hepatocellular carcinoma treatment using PhotoDox (I-CPT). Gal Shafirstein's group at Roswell Park collaborates on interstitial chemo-phototherapy development. Part of $2M NIH-NCI Phase II STTR.
  • EuBiologics Co., Ltd.flagshipStrategic or Co-development PartnerSouth Korean pharmaceutical partner co-developing multiple vaccines using POP BIO's SNAP technology. Partnership on EuCorVac-19 (COVID-19, Phase 3 completed), RSV vaccine (Phase 1), shingles vaccine (Phase 1). EuBiologics provides antigen production, EcML adjuvant, and manufacturing scale-up with capacity for hundreds of millions of doses.
  • EuPOP Life SciencesflagshipStrategic or Co-development PartnerJoint venture between POP BIO and EuBiologics based in Buffalo, NY for global commercialization of vaccines using POP BIO's SNAP platform and EuBiologics' EcML adjuvant technology. Advancing RSV, shingles, and Alzheimer's disease vaccines toward clinical trials.
  • University at BuffalocoreStrategic or Co-development PartnerPOP BIO operates from SUNY Buffalo incubator at Baird Research Park. Co-founder Dr. Jonathan Lovell developed the PoP technology at University at Buffalo. Ongoing research collaborations for vaccine development.
  • SUNY Upstate Medical UniversitysupportingStrategic or Co-development PartnerInternational research team collaboration for SNAP platform development against Disease X threats.
  • National Institute of Infectious Diseases (Japan)supportingStrategic or Co-development PartnerInternational research team collaboration as part of CEPI-funded SNAP platform project for SFTS and Disease X preparedness.
  • New York State Institute for Basic Research in Developmental DisabilitiessupportingStrategic or Co-development PartnerCollaboration on Alzheimer's immunotherapy with Dr. Chunling Dai as co-investigator. Part of $2.46M NIH Phase II STTR grant for mosaic SNAP active immunotherapy development.
  • University of Puerto RicosupportingStrategic or Co-development PartnerCollaboration on Alzheimer's immunotherapy research as part of NIH-funded mosaic SNAP vaccine program.
  • Janssen Vaccines (Johnson & Johnson)supportingStrategic or Co-development PartnerCollaboration resulted in HIV-1 vaccine candidate research published in Nature Communications. SNAP platform used with HIV-1 Env trimers to generate cross-clade neutralizing antibody immunity.
  • NCI Nanotechnology Characterization LaboratorysupportingStrategic or Co-development PartnerPOP BIO's cancer vaccine concept accepted into NCL's Assay Cascade characterization program for rigorous evaluation including sterility, endotoxin testing, physicochemical characterization, and in vivo studies to promote clinical translation.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

POP Biotechnologies competitors and assessment

Company assessment

Broad incumbents

  • GSK Vaccines: GSK's vaccines business is a global leader with established franchises in shingles (Shingrix), HPV, and influenza. Directly relevant as the dominant commercial competitor in the shingles vaccine category where POP BIO's EuHZV is in Phase 1.
  • Sanofi Pasteur: Sanofi Pasteur is one of the world's largest vaccine manufacturers with a portfolio spanning influenza, pediatric, and travel vaccines. Represents the established incumbent in the vaccine market that POP BIO's partnered programs ultimately compete against for share.
  • BioNTech: BioNTech pioneered mRNA vaccine technology and partnered with Pfizer for the Comirnaty COVID-19 vaccine. Its platform addresses infectious disease and oncology, directly overlapping with POP BIO's target therapeutic areas and partnership-driven GTM model.
  • Moderna: Moderna is the leading mRNA vaccine platform company, with an established commercial COVID-19 vaccine franchise and pipeline spanning infectious disease, oncology, and rare disease. It represents the dominant competitive force in rapid-response vaccine development that POP BIO's SNAP platform must differentiate against.

Direct peers

  • Soligenix: Soligenix is a late-stage clinical biopharmaceutical company developing vaccines and therapeutics for infectious disease and rare conditions. Comparable as a small, clinical-stage vaccine biotech pursuing partnered development of platform-derived products.
  • Dynavax Technologies: Dynavax specializes in vaccine adjuvants (CpG 1018) and commercializes hepatitis B and COVID-19 vaccines. Comparable as a vaccine platform company whose adjuvant technology (similar to EuBiologics' EcML used with SNAP) is central to its partnership-based business model.
  • VBI Vaccines: VBI Vaccines is a clinical-stage vaccine platform company developing enveloped virus-like particle (eVLP) vaccines for infectious disease and immuno-oncology. Comparable as a small-cap, platform-licensed vaccine developer pursuing partnership-driven commercialization.
  • Gritstone bio: Gritstone bio develops neoantigen-based cancer vaccines and infectious disease vaccines using a self-amplifying mRNA platform combined with adenoviral vectors. Comparable as a clinical-stage biotech applying vaccine platform technology to oncology and infectious disease indications.
  • Novavax: Novavax develops protein nanoparticle vaccines using recombinant nanoparticle technology with a built-in Matrix-M adjuvant, making it the closest structural analog to POP BIO's SNAP/CoPoP liposome platform. Both companies target infectious disease vaccine indications and pursue licensing/partnership models with global manufacturers.

Emerging players

  • CureVac: CureVac is an mRNA technology company developing prophylactic vaccines and cancer immunotherapies. Comparable as a platform-based vaccine developer pursuing infectious disease and oncology applications, though with a different underlying technology than POP BIO's liposome-based SNAP platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

POP Biotechnologies social profiles

Digital presence

POP Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

POP Biotechnologies leadership team

Management profile

Number of profiles

Profiles3 records

POP Biotechnologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

POP Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

POP Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about POP Biotechnologies

What does POP Biotechnologies do?

POP Biotechnologies develops proprietary porphyrin-phospholipid (PoP) liposome-based nanomedicine platforms, centered on the SNAP (Spontaneous Nanoliposome Antigen Particleization) vaccine platform that uses cobalt-modified CoPoP liposomes to rapidly display antigens. The company licenses this platform to pharmaceutical partners (notably EuBiologics) for co-development and commercialization of vaccines (COVID-19, RSV, shingles, influenza, H5N1, Alzheimer's) and develops the PhotoDOX light-activated chemotherapy product for solid tumors.

Is POP Biotechnologies a public or private company?

POP Biotechnologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was POP Biotechnologies founded?

POP Biotechnologies was founded in 2016. It employs 1 to 10 people.

Where is POP Biotechnologies based?

POP Biotechnologies is headquartered in Buffalo, United States, in the North America region.

How does POP Biotechnologies make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are government Grants and Funding and co-development and Joint Ventures.

Who are POP Biotechnologies's main competitors?

Broad incumbents on record are GSK Vaccines, Sanofi Pasteur, BioNTech and Moderna. Direct peers are Soligenix, Dynavax Technologies, VBI Vaccines, Gritstone bio and Novavax. CureVac is listed as an emerging player.

Does POP Biotechnologies have an API?

No public API is recorded for POP Biotechnologies.

What industry is POP Biotechnologies in?

POP Biotechnologies's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals